1. Home
  2. PXED vs GERN Comparison

PXED vs GERN Comparison

Compare PXED & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PXED

Phoenix Education Partners Inc.

N/A

Current Price

$30.16

Market Cap

1.0B

Sector

Real Estate

ML Signal

N/A

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

821.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PXED
GERN
Founded
1976
1990
Country
United States
United States
Employees
3400
258
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
821.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PXED
GERN
Price
$30.16
$1.26
Analyst Decision
Buy
Hold
Analyst Count
7
3
Target Price
$44.29
$2.17
AVG Volume (30 Days)
71.6K
14.2M
Earning Date
04-07-2026
05-06-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.85
$26.91
Revenue Next Year
$4.49
$43.75
P/E Ratio
$11.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.52
$1.04
52 Week High
$38.19
$2.01

Technical Indicators

Market Signals
Indicator
PXED
GERN
Relative Strength Index (RSI) 53.45 32.94
Support Level $28.40 $1.24
Resistance Level $30.85 $1.29
Average True Range (ATR) 1.37 0.09
MACD -0.01 -0.02
Stochastic Oscillator 57.47 10.42

Price Performance

Historical Comparison
PXED
GERN

About PXED Phoenix Education Partners Inc.

Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: